Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [HEALTH]

7 clusters · 29 sources · 70 days · First seen 2 months ago · Last updated 6 days ago

Kratom regulation and safety in the United States

Overview

Kratom occupies a complex regulatory position in the United States. While the FDA has not scheduled the botanical product, it has stated that no kratom-containing products are legally marketed as prescription drugs, over-the-counter drugs, or dietary supplements.

Research from the University of Florida indicates that many commercially available products are frequently mislabeled. There is growing concern regarding the rise of 7-hydroxymitragynine (7-OH), a potent derivative that can exceed the potency of morphine. This shift in composition has coincided with a 67.8 percent increase in reported kratom or 7-OH poisoning symptoms at U.S. poison centers over the past year.

Regulatory pressure is intensifying at both federal and local levels. The DEA has announced its intent to temporarily place certain concentrated kratom-derived products, specifically 7-OH and mitragynine pseudoindoxyl, into Schedule I if they exceed certain thresholds. This move, supported by the FDA and HHS, could result in a formal scheduling order as early as November 13. This follows previous emergency bans on compounds like MGPI, MGM-15, and MGM-16.

Locally, Missoula County, Montana, will prohibit kratom sales in retail food businesses starting in November, citing 29 overdose deaths in the state between 2020 and 2025. In Florida, Hillsborough County commissioners unanimously voted to move forward with an ordinance targeting 7-OH. The proposal aims to restrict the concentrated byproduct while leaving the natural herbal form legal for those aged 21 and older, amid concerns that a statewide emergency ban on synthetic products may expire next year.

Entities

Drug Enforcement Administration · Department of Health and Human Services · Department of Justice · University of Florida College of Pharmacy · Utah Poison Control Center

Claims

What the coverage asserts, and how many sources carry each claim.

[○ 1 SOURCE] Mountainside Treatment Center has observed an increase in admissions for 7-hydroxymitragynine (7-OH) dependence.
[○ 1 SOURCE] Mountainside recorded 184 admissions involving kratom use in 2025, compared to 67 in 2024.
[○ 1 SOURCE] Connecticut classified kratom, including its leaves, stems, extracts, and 7-OH, as a Schedule I controlled substance effective March 25.
[○ 1 SOURCE] A temporary one-year ban on all forms of kratom took effect in Massachusetts on August 28.
[○ 1 SOURCE] The American Kratom Association argues that regulations are sufficient to ensure safety rather than bans.
[○ 1 SOURCE] Utah stopped sales of kratom products that are not pure leaf kratom in May 2026 and raised the purchasing age to 21.

Timeline

6 days ago

[POLITICS] 2 sources
Hillsborough County considers ban on potent kratom compound
Hillsborough County commissioners voted to advance an ordinance targeting 7-hydroxymitragynine, a potent compound found in some kratom supplements, while leaving natural kratom legal.
7 days ago

[POLITICS] 3 sources
US authorities move to restrict kratom and its derivatives
US authorities are tightening controls on kratom, with Missoula County banning retail food sales and the DEA proposing to classify concentrated 7-OH derivatives as Schedule I substances.
28 days ago

[HEALTH] 3 sources
Kratom regulation intensifies across several U.S. states
U.S. states are increasingly implementing bans or stricter regulations on kratom as clinicians report rising dependence on its potent compounds and legislators weigh public safety against industry concerns.
about 2 months ago

[HEALTH] 5 sources
Kratom regulation debates intensify in Pennsylvania and New York
Lawmakers in Pennsylvania and grieving families in New York are pushing for stricter controls or bans on kratom due to concerns over its opioid-like effects and potential for overdose.
about 2 months ago

[CRIME] 11 sources
U.S. Department of Justice bans three kratom derivatives
The U.S. Department of Justice has emergency-scheduled three potent kratom derivatives as Schedule I substances due to their high potential for abuse and opioid-like effects.
2 months ago

[HEALTH] 3 sources
Kratom products frequently mislabeled and increasingly potent, studies find
Studies and medical reports reveal that many kratom products are mislabeled and increasingly contain potent synthetic derivatives like 7-OH, leading to rising poisoning rates and acute withdrawal.
2 months ago

[HEALTH] 2 sources
Kratom regulation and consumer safety in the United States
Kratom occupies a regulatory middle ground in the US, lacking FDA dietary supplement oversight and relying heavily on industry self-regulation and consumer vigilance regarding testing and labeling.

Sources

abc17news.com · americafirstreport.com · conservativedailynews.com · dailymemphian.com · fairfieldsuntimes.com · fl-counties.com · fox13news.com · gloucestercitynews.net · governing.com · greenwichfreepress.com · haberaktuel.com · invisibel.net · kiow.com · krdo.com · kvia.com · lakevillejournal.com · messengernews.net · missoulacurrent.com · montanafreepress.org · portaldoenvelhecimento.org.br · reason.com · research.ufl.edu · sciencealert.com · sltrib.com · thelifesciencesmagazine.com · triblive.com · troyrecord.com · wnyt.com · yonkerstimes.com

This summary has been updated 6 times: see revision history